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Abstract 
Background:  Patients on haemodialysis are at high risk for cardiovascular events, but heart failure 
and sudden death are more common than atherosclerotic events. The AURORA trial was designed to 
assess the effect of rosuvastatin on myocardial infarction and death from any cardiac cause in 2773 
haemodialysis patients. We studied predictors of the atherosclerotic cardiovascular events in 
AURORA.  
Methods: We readjudicated all deaths and presumed myocardial infarctions according to the criteria 
used in the Study of Heart and Renal Protection (SHARP); these were specifically developed to 
separate atherosclerotic from non-atherosclerotic cardiovascular events. The readjudicated 
atherosclerotic endpoint included first event of the following: non-fatal myocardial infarction, fatal 
coronary heart disease, non-fatal and fatal non-haemorrhagic stroke, coronary revascularisation 
procedures and death from ischaemic limb disease. Step-wise Cox regression analysis was used to 
identify the predictors of such events. 
Results: During a mean follow-up of 3.2 years, 506 patients experienced the new composite 
atherosclerotic outcome. Age, male sex, prevalent diabetes, prior cardiovascular disease, weekly 
dialysis duration, baseline albumin (HR 0.96; 95% CI 0.94-0.99 per g/L increase), high sensitive CRP 
(HR 1.13; 95% CI 1.04-1.22 per mg/L increase) and oxidised LDL cholesterol (HR 1.09; 95% CI 1.03-
1.17 per 10 U/L increase) were selected as significant predictors in the model. Neither LDL 
cholesterol nor allocation to placebo/rosuvastatin therapy predicted the outcome.  
Conclusions: Even with the use of strict criteria for endpoint definition, non-traditional risk factors, 
but not lipid disturbances, predicted atherosclerotic events in haemodialysis patients. 
 
Keywords:  Haemodialysis  Atherosclerosis  Coronary Artery Disease
   Statins  Survival analysis  Vascular calcification 
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Short summary: 
In the large randomised controlled trials of statin treatment in dialysis patients, cardiovascular 
disease has been classified using diverging code rules, and atherosclerotic events have been defined 
differently. We recadjudicated all fatal events and all events originally classified as non-fatal 
coronary heart disease in the AURORA trial using the code rules applied in SHARP, and we assessed 
predictors of atherosclerotic cardiovascular events only. In spite of the strict definition used for 
atherosclerotic diseases, we found that neither LDL cholesterol, total cholesterol nor randomisation 
to statin or placebo treatment predicted the new endpoint, whereas non-traditional risk factors such 
as hypoalbuminaemia, high sensitive CRP and oxidised LDL were significant predictors. 
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Introduction 
Although survival in patients on haemodialysis (HD) has improved during the last two decades [1, 2], 
adjusted mortality rates are still high [1]. In prevalent dialysis patients, cardiovascular disease (CVD) 
is the leading cause of death, accounting for approximately 40% of all deaths [1, 2]. 
The use of strategies to lower low density lipoprotein (LDL) cholesterol, including statins, as 
prevention against coronary heart disease (CHD) and other atherosclerotic vascular diseases is well-
established in the general population [3]. In patients with chronic kidney disease (CKD), however, 
and particularly in patients on maintenance dialysis, sudden cardiac death and heart failure 
predominate [4-6], and traditional risk factors for atherosclerosis, such as hyperlipidaemia, appear 
to play a less prominent role. Instead, non-traditional risk factors including uraemic toxins, markers 
of mineral bone disorder and vascular calcification, inflammation, oxidative stress and fluid overload 
[6] have been associated with increased CVD risk in this population. Nevertheless, traditional 
cardiovascular risk factors (e.g. hypertension and dyslipidaemia), as well as atherosclerotic diseases, 
are commonly observed in haemodialysis (HD) patients. [7, 8].  
Two large randomised controlled trials, the A Study to Evaluate the Use of Rosuvastatin in Subjects 
on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) and Die 
Deutsche Diabetes Dialyse Studie (4D), were designed to test whether statin treatment could 
improve cardiovascular morbidity and mortality in HD patients [9, 10]. Both failed to demonstrate a 
significant benefit of LDL-lowering therapy on the primary vascular end-points. Although the lack of 
interaction between treatment allocation and dialysis status at baseline (yes/no) in the Study of 
Heart and Renal Protection (SHARP) contradicted a subgroup difference, no significant treatment 
effect of simvastatin plus ezetimibe was observed when the dialysis subgroup was considered in 
isolation [11].  In AURORA, which so far is the largest randomised statin trial conducted solely in 
patients on dialysis, the primary outcome was a composite endpoint of atherosclerotic and non-
atherosclerotic cardiovascular events. The reported percentage of deaths attributable to CHD was 
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three times the percentage reported in 4D and four times the reported incident rate in the dialysis 
subgroup in SHARP [11]. Although inclusion criteria and treatment strategy varied slightly between 
the three trials (Table 1), the dissimilarities in outcome incidence have been attributed to differences 
in coding rules used to ascribe deaths to CHD in these trials.  
In order to separate atherosclerotic from non-atherosclerotic cardiovascular events in AURORA, we 
readjudicated all fatal events and non-fatal coronary events according to criteria specifically 
developed to separate atherosclerotic from non-atherosclerotic cardiovascular events in kidney 
disease, i.e. the same criteria that were used in SHARP. The aim of the present study was to assess 
predictors of a combined atherosclerotic cardiovascular endpoint similar to the main outcome in 
SHARP. 
 
Subjects and Methods 
Study Cohort and the Design of the AURORA Trial 
The design, baseline data and main results of the AURORA trial have been published previously [9, 
12]. In short, in 2003-2004, 2,773 male and female prevalent HD patients (treated for ≥3 months), 
aged 50-80 years, from 280 centres in 25 countries across the world were randomised 1:1 to receive 
either rosuvastatin 10 mg per day or placebo. The mean follow-up time was 3.2 years. The primary 
composite endpoint was time to a major cardiovascular event, defined as non-fatal myocardial 
infarction, non-fatal stroke, or death from cardiovascular causes. A sudden, unexpected death was 
attributed to CHD (definite or suspected) if there was inadequate information to ascribe a non-
cardiovascular cause. All events were adjudicated by an independent endpoint committee blinded to 
treatment allocation. The study (clinicaltrials.gov identifier number NCT00240331) was conducted in 
accordance with the ethical principles of the Declaration of Helsinki, the Good Clinical Practice 
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guidelines of the International Conference of Harmonisation, and local regulatory requirements at all 
participating centres. 
 
Readjudication of fatal and non-fatal events 
In 2014 and 2015, all fatal events and all events originally classified as definite or suspected non-fatal 
myocardial infarctions were readjudicated according to criteria identical to those used in SHARP 
[11]. Non-fatal and fatal coronary events were classified as definite, probable or possible. A death 
was attributed to acute CHD if diagnosed by post-mortem examination and no other probable cause 
of death was revealed, or on the basis of clinical criteria. Typical (chest pain) or atypical (pulmonary 
oedema, syncope or shock) coronary symptoms were a prerequisite for the clinical diagnosis of all 
CHD, and ECG and myocardial biomarkers were reviewed according to strict criteria. In order to be 
attributed to CHD, death must have occurred within 28 days of the coronary event and no other 
cause of death must have been recorded. A sudden, unexpected death was not assigned a coronary 
cause unless supported by ECG, biomarkers or autopsy. Using the overriding principles set out by the 
International Statistical Classification of Disease and Related Health Problems 10th Revision (ICD-10), 
“the disease or injury which initiated the chain of morbid events leading directly to death” was 
recorded as the cause of death. 
The readjudications were completed by two experienced clinicians who were blinded to treatment 
allocation, other exposure data and the original event adjudication. In case of doubts, the event was 
discussed by two consultants. Also, random cases were evaluated by both consultants to ensure 
coherent adjudication. 
The new composite atherosclerotic endpoint comprised first event of the following: definite, 
probable or possible non-fatal myocardial infarction or fatal CHD, coronary revascularisation 
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procedures and non-fatal or fatal non-haemorrhagic or unspecified stroke. In addition, death from 
peripheral artery disease (PAD) was included in the endpoint. 
 
Statistical analyses 
Originally, 805 primary events were required for 87% power to reveal a 19.5% lower incidence rate 
in the AURORA treatment group [9]. The readjudication process resulted in a considerably lower 
number of events. Thus, the statistical power to assess the treatment effect of rosuvastatin on the 
new endpoint was reduced. However, we chose to run the intention-to-treat analysis, using an 
unadjusted Cox regression model and producing a Kaplan-Meier survival curve. All other analyses in 
the present study were done in the entire AUROA cohort with no regards to treatment allocation.  
Data are presented as mean (standard deviation [SD]) or number (%) as appropriate. Differences in 
baseline risk factors between patients who did or did not experience the new composite endpoint 
were assessed using two-tailed independent samples t-tests or chi square tests, as appropriate. 
Crude incidence rates of each atherosclerotic endpoint were calculated as events per 1000 person 
years at risk. 
Cox proportional hazard regression analyses were run to assess the impact of baseline risk factors on 
the composite atherosclerotic endpoint. We calculated the univariate hazard ratios (HR) and 95% 
confidence intervals (CI) for the following potential predictors: demographics (sex, age, geographic 
region) comorbidity (diabetes, history of CVD, history of CHD), lipids (total cholesterol, LDL 
cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides), other traditional risk factors 
(body weight and height, body mass index, current smoking, systolic and diastolic blood pressure, 
pulse pressure), dialysis specific risk factors (HD vintage, weekly duration of HD treatment, dialysis 
quality measured as Kt/V), other non-traditional or uraemia-specific risk factors and inflammation 
markers (phosphate, calcium, albumin, haemoglobin, haematocrit and high sensitive C-reactive 
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protein [hsCRP]). Oxidised LDL cholesterol and apolipoprotein (Apo) B/Apo A1ratio may be 
characterised as markers of lipid disturbances or inflammation and were also assessed as predictors. 
Finally, current medication use (beta-blockers, inhibitors of the renin-angiotensin-system, 
sevelamer) and randomised treatment allocation (rosuvastatin vs. placebo) were entered into 
univariate Cox models. 
All variables with a P<0.1 for univariate association with the atherosclerotic endpoint were included 
in a backwards step-wise Cox regression model to obtain the independent risk factors. 
The same procedure was repeated for each subgroup of events: CHD (fatal or non-fatal myocardial 
infarction and/or coronary revascularisation), non-haemorrhagic or unspecified stroke (fatal or non-
fatal) and death from PAD. 
Non-linear associations with the main endpoint were assessed in univariate Cox regression models 
for each predictor categorised into quartiles.  
The proportional hazard assumption for each Cox model was checked using a global test of scaled 
Schoenfeld residuals against time. Analyses were run using IBM SPSS Statistics Software version 20 
(IBM Corp., Armonk, NY) and Stata Statistical Software 11 (StataCorp LP, TX). Two-sided P values 
<0.05 were considered statistically significant. 
 
Results 
Baseline Risk Factors  
Baseline characteristics for patients according to whether they did or did not experience the new 
composite endpoint are presented in Table 2. The 506 patients who had at least one atherosclerotic 
event during follow-up were more frequently men, older and had a higher prevalence of diabetes 
and previous CVD at baseline than the 2267 patients with no reported atherosclerotic event. 
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However, lipid values other than HDL cholesterol, systolic blood pressure and frequency of current 
smoking did not differ significantly between the two groups. The event group had significantly lower 
albumin and higher levels of markers of inflammation and oxidative stress including hsCRP, oxidised 
LDL and Apo B/Apo A1 ratio. These patients also had longer HD treatment per week, whereas 
dialysis vintage and quality were similar. Patients from Western Europe were over-represented in 
the endpoint-group compared to the group without atherosclerotic events, whereas the opposite 
was found for patients from South-America. 
 
The Combined Atherosclerotic Endpoint and Predictor Assessment  
There were 506 patients who experienced at least one atherosclerotic event. Some patients had 
more than one non-fatal event. The numbers of first event within each sub-group of atherosclerotic 
disease, as well as crude incidence rates, are given in Table 3. The composite endpoint included 120 
non-fatal and 78 fatal CHD events, 180 coronary revascularisation procedures, 71 non-fatal and 28 
fatal non-haemorrhagic and unspecified strokes and 29 deaths due to PAD.  
There was no significant effect of allocation category (rosuvastatin or placebo) on the new endpoint 
(Figure 1 and Table 4).  
The univariate and multivariable associations between traditional and non-traditional risk factors 
and the readjudicated atherosclerotic endpoint are displayed in Table 4. LDL cholesterol was not 
significantly associated with the endpoint in univariate analyses. Thus, neither LDL cholesterol nor 
treatment allocation were included in the multivariable model. Significant association with the 
composite endpoint was found for HDL cholesterol, Apo B/Apo A1 ratio and oxidised LDL in 
univariate analyses. In multivariable analysis age, male sex, diabetes and prevalent CVD significantly 
predicted the atherosclerotic endpoint, whereas no parameter reflecting hyperlipidaemia were 
independent predictors. Hypoalbuminaemia, increased hsCRP and oxidised LDL cholesterol were 
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independent non-traditional predictors of the combined endpoint. Patients from South-America had 
a lower HR for the combined endpoint than patients from other geographical regions. A non-linear 
association was found between dialysis vintage and the atherosclerotic endpoint, with dialysis 
vintage in the second quartile (1.0 - 2.3 years) predicting significantly reduced risk of events 
compared to the fourth quartile (>4.4 years), and a non-significant trend towards higher event risk in 
the first quartile. In multivariable analysis with the categorised dialysis vintage variable, estimates 
were essentially unchanged, apart from weekly HD duration loosing and phosphate gaining 
statistical significance (data not shown). No other variables exhibited a non-linear association with 
the endpoint. Collinearity/multicollinearity did not affect any of the multivariable analyses.  
 
Predictors of CHD, Ischaemic Stroke and Death from PAD 
During follow-up, 384 persons had at least one non-fatal or fatal myocardial infarction and/or 
underwent coronary revascularisation (Tables 3 and 5). In univariate Cox regression analyses, several 
traditional (age, sex, previous CHD and CVD, diabetes, body weight and height, low diastolic blood 
pressure and low HDL cholesterol) and non-traditional (dialysis duration, hsCRP and low albumin) 
risk factors predicted CHD. An elevated Apo B/Apo A1 ratio was also associated with this endpoint 
(Table 5). LDL cholesterol was not a significant predictor of CHD (HR per mmol/L increase 1.03 (95% 
CI 0.92 – 1.15; P=0.59), and neither was randomisation category (P=0.96). Both univariate and 
multivariable analyses of predictors for CHD mimicked the results for the combined atherosclerotic 
endpoint, but Apo B/Apo A1 ratio remained significantly associated with CHD in the fully adjusted 
models.  Furthermore, elevated serum phosphate independently predicted CHD.  
There were only 116 patients who had at least one episode of non-haemorrhagic or unspecified 
stroke (non-fatal or fatal), and 50 patients died from PAD, limiting the power to study these 
outcomes in isolation. Age and hypoalbuminaemia independently predicted stroke in the 
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multivariable Cox regression analysis (Table 6). High serum phosphate strongly predicted death from 
PAD, as did prevalent diabetes, previous CVD, hypoalbuminaemia, higher LDL cholesterol and higher 
hsCRP (Table 7). 
 
Discussion 
In a large cohort of prevalent HD patients, we found that elevated LDL cholesterol was not selected 
as a predictor of the new composite atherosclerotic endpoint, despite a strict definition of 
atherosclerosis according to the SHARP criteria. Traditional risk factors were mainly non-modifiable 
(higher age, sex, diabetes and a history of CVD). Moreover, the model identified non-traditional risk 
factors, including hypoalbuminaemia and biomarkers of oxidative stress and inflammation, as 
significant predictors of atherosclerotic events, similar to previously published predictors of all major 
cardiovascular events in AURORA [13]. 
In the general population, atherosclerosis dominates as the pathological substrate for CVD. CHD is 
the major cause of cardiovascular morbidity and mortality, and the Framingham risk score is a 
validated tool for risk prediction [14]. The same tool has been evaluated to be less useful in patients 
with CKD not on dialysis [15].  In patients on chronic HD, cardiac diseases such as heart failure [16, 
17] and sudden death [4], surpass the classic atherosclerotic disorders. Nevertheless, coronary 
pathology is common in advanced stages of CKD [5, 8, 17, 18], and atherosclerotic diseases infer a 
worse prognosis in this patient group than in non-CKD patients [19, 20]. Therefore, assessment of 
predictors of this subset of CVD is of considerable importance also in patients on maintenance 
dialysis. 
Available data about predictors of atherosclerotic CVD in dialysis patients is limited, with studies 
often considering cardiovascular events overall [16, 21, 22] or relying on less accurate death registry 
reports [23, 24]. Furthermore, there are no agreed criteria on which to distinguish atherosclerotic 
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from non-atherosclerotic CVD in trials [9-11, 25]. Partly, these variations reflect challenges in 
diagnosing atherosclerotic events in HD patients [26]. For example, dialysis patients with acute 
coronary syndrome often have atypical symptoms [26, 27], ST elevations are observed less 
frequently [26, 28], and myocardial biomarkers have low sensitivity and specificity to diagnose the 
disease [29].  
Despite the effort to separate non-atherosclerotic from atherosclerotic events that was made in the 
present study, there may be a substantial overlap and no clear-cut differences between these 
diseases in prevalent dialysis patients. Vascular calcification, which is associated with CVD and 
mortality, is common. [30, 31]. Coronary atherosclerotic lesions are characterised by marked 
calcifications consisting of hydroxylapatite and calcium-phosphate, increased media thickness and 
reduced lumen area [32]. Phosphate is among the promoters of progressive calcification and a 
strong predictor of adverse outcome in dialysis patients [33]. In our study, phosphate did not predict 
the composite endpoint, but independently predicted CHD and death from PAD. This is in agreement 
with the reported discoveries of calcium-phosphate rich coronary plaques that may differ from 
atherosclerotic plaques in non-CKD patients. There is substantial evidence suggesting that risk 
scoring as well as preventive interventions in this patient group cannot be adopted directly from 
guidelines developed for other risk groups [34, 35].  
The fact that oxidised LDL cholesterol was significantly associated with atherosclerotic events is of 
interest. Oxidatively modified LDL cholesterol particles exhibit proinflammatory and proatherogenic 
effects in vessel walls, including chemoattractant, cytotoxic and cytokine stimulatory effects. 
Monocytes have effective uptake mechanisms for these modified LDL cholesterol molecules, 
facilitating the formation of foam cells [36]. Conflicting data have been published regarding levels of 
oxidised LDL in dialysis patients. Whereas one study reports nearly 10 times higher levels [37], 
others have reported no difference [38] or even lower values [39] in dialysis patients compared with 
healthy individuals. Furthermore, whether oxidised LDL cholesterol primarily is a marker of lipid 
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disturbances or indicates oxidative stress, has not yet been agreed upon [39, 40]. Nevertheless, in 
our study LDL cholesterol was associated with death from PAD, and Apo B/Apo A1 ratio predicted 
CHD. A recent meta-analysis that included placebo controlled statin trials in patients on 
maintenance dialysis, confirmed a hsCRP lowering effect from statin treatment [41]. A post hoc 
analysis from the 4D study demonstrated significant risk reduction by atorvastatin in HD patients 
with pre-treatment LDL cholesterol level in the highest quartile. At baseline, this group also had 
lower serum albumin and higher hsCRP [42].   Therefore, it cannot be ruled out that both an 
atherogenic lipoprotein profile and chronic inflammation are risk factors that may be available for 
intervention in a subset of prevalent HD patients.  
The AURORA cohort consisted of prevalent HD patients who had been on maintenance dialysis for 
median 28.0 months [12].  Dialysis vintage has been shown to predict progression of vascular 
calcification [43-45], whereas traditional risk factors, including LDL cholesterol, do not increase with 
increasing duration of HD treatment  [46]. One may speculate that “traditional” atherosclerosis 
associated with traditional risk factors becomes less common, whereas vascular calcification, not 
readily accessible for established preventive measures, becomes increasingly important with 
increasing time on HD.  
We found a significantly lower risk of CHD and atherosclerotic events in patients dialysed in South 
America compared to the other geographic regions. This phenomenon probably reflects differences 
in diagnosis and reporting of CHD in this region, as well as a higher incidence of other causes of 
death during the study period. 
The incidence rate of ischaemic stroke is high in HD patients [47, 48]. Older age and diabetes have 
consistently been reported to be associated with ischaemic stroke in HD cohorts [47, 48]. In the 
present study, only high age and hypoalbuminaemia were selected as predictors, but the number of 
strokes was low, and the results should be interpreted with caution. 
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Important strengths of our study were the large cohort of well-characterised, prevalent HD patients 
from 25 different countries worldwide. Furthermore, each event was readjudicated by clinicians 
according to validated criteria. However, residual confounding due to measurement error, 
unmeasured risk factors and the lack of adjustment for time varying covariates during follow-up 
constitute important limitations. The observational study design, and in particular the use of 
statistical models that selected predictors in an automated fashion, precludes causal inferences, and 
the lack of associations between traditional risk factors and the atherosclerotic endpoint, should be 
interpreted with caution.  As discussed above, a clear separation between atherosclerotic and non-
atherosclerotic events is difficult in patients on dialysis, and misclassifications may have interfered 
with our results. Therefore, we cannot exclude the possibility that a clinically significant association 
between hyperlipidaemia and a subset of atherosclerotic events may exist in prevalent HD patients. 
Moreover, our results may not be generalizable to younger dialysis populations with shorter HD 
vintage.  
In conclusion, this post hoc analysis from the AURORA trial confirmed that modifiable traditional risk 
factors including lipid disturbances did not predict atherosclerotic cardiovascular events in prevalent 
HD patients. The events were adjudicated with the use of strict and validated criteria. Markers of 
inflammation and oxidative stress were significant predictors, and future studies should further 
evaluate the relevance of these markers and whether they may be targets for novel treatment 
strategies in patients on dialysis. 
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Table 1. Study design of the main trials assessing the effect of LDL cholesterol lowering agents in patients on dialysis.  
  Inclusion criteria Treatment strategy Pre-defined endpoints 
AURORA LDL cholesterol of any value Rosuvastatin 10 mg vs. placebo Primary endpoint 
 
 
 
 
 Time to MACE  
 Men and women aged 50-80 years   (non-fatal myocardial infarction,  
 
ESRD and chronic haemodialysis for ≥3 
months   non-fatal stroke, 
     death from a cardiovascular cause) 
     
   Secondary endpoints 
    All-cause mortality 
    Cardiovascular event-free survival 
      Death from a cardiovascular cause 
      Death from a non-cardiovascular cause 
      Coronary or peripheral revascularisation 
      Procedure for stenosis or thrombosis of the vascular access* 
     
SHARP LDL cholesterol of any value Ezetimibe 10 mg/simvastatin 20 mg Primary endpoint    
 vs. placebo  
 
Time to major atherosclerotic event 
 
Men and women ≥40 years   (non-fatal myocardial  infarction, coronary 
 History of CKD   death, non-haemorrhagic stroke, arterial 
  Blood creatinine ≥150 µmol/L in    revascularisation procedure) 
  men or ≥130 µmol/L in women      
  On dialysis (haemodialysis or   Secondary endpoints 
  peritoneal dialysis)   Each separate component of the primary 
    endpoint 
    Major vascular event (primary endpoint, 
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    non-coronary cardiac death, haemorrhagic   
    stroke) 
      Commencement of chronic dialysis 
      or kidney transplantation 
      
4D 
Fasting LDL cholesterol ≥2.1 mmol/L 
and ≤4.9 mmol/L Atorvastatin 20 mg vs. placebo Primary endpoint 
    Time to MACE 
    (fatal myocardial infarction, sudden death,  
 Men and women aged 18-80 years   death from congestive heart failure, death from  
 Chronic haemodialysis for ≤2 years   diagnostic or therapeutic procedure due to coronary   
    artery disease, death from another coronary cause,  
    non-fatal myocardial infarction, non-fatal or fatal stroke) 
     
   Secondary endpoints 
    All-cause mortality 
    Cardiovascular event (cardiovascular death, 
    myocardial infarction, coronary intervention procedure) 
    Cerebrovascular event (stroke, transient ischaemic attack) 
    Death from non-cardiovascular causes stratified by 
    cause 
        Changes in lipid levels relative to baseline 
LDL: low density lipoprotein. ESRD: End stage renal disease. MACE: Major adverse cardiac event. CKD: chronic kidney disease. *Arteriovenous fistula or graft used for  
chronic haemodialysis 
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Table 2. Baseline characteristics of the patients who did and did not experience the combined atherosclerotic 
endpoint during follow-up.  
    
Patients with 
endpoint (n=506) 
Patients without 
endpoint (n=2267) P-value 
Sex, male, n (%)  353 (69.8) 1370 (60.4) <0.001 
Age, years  66.6 ±8.5 63.7 ±8.6 <0.001 
Randomised to rosuvastatin, n (%) 253 (50.0) 1136 (50.0) 0.96 
Region, n (%)      <0.001 
 Western Europe 308 (60.9) 1108 (48.9)  
 Eastern Europe 107 (21.1) 480 (21.2)  
 Asia 10 (2.0) 72 (3.2)  
 South-America 23 (4.5) 323 (14.2)  
 Other 58 (11.4) 284 (12.5)  
Systolic blood pressure, mm Hg 136 ±25 137 ±24 0.23 
Diastolic blood pressure, mm Hg 74 ±13 76 ±13 <0.001 
Height, cm  167.9 ±9.4 166.7 ±9.8 0.014 
Weight, kg  72.6 ±14.4 70.5 ±15.7 0.004 
Body mass index, kg/m2 25.7 ±4.7 25.3 ±5.0 0.11 
Current smoking, n (%) 83 (16.4) 346 (15.3) 0.52 
Previous coronary heart disease, n (%) 355 (70.2) 1069 (47.2) <0.001 
Previous cardiovascular disease, n (%) 299 (59.1) 806 (35.6) <0.001 
Diabetes, n (%)  182 (36.0) 549 (24.2) <0.001 
Cholesterol, mmol/L 4.60 ±1.12 4.52 ±1.09 0.17 
LDL cholesterol, mmol/L 2.63 ±0.91 2.56 ±0.89 0.13 
HDL cholesterol, mmol/L 1.13 ±0.37 1.17 ±0.40 0.043 
Triglycerides, mmol/L 1.82 ±1.11 1.74 ±1.07 0.16 
Oxidised LDL cholesterol, U/L 36.0 ±15.9 33.8 ±13.2 0.004 
Apolipoprotein B /Apolipoprotein A1 ratio 0.73 ±0.26 0.69 ±0.25 0.001 
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Beta blocker, n (%) 206 (40.7) 826 (36.6) 0.09 
ACEi or ARB, n (%) 194 (38.3) 826 (36.6) 0.47 
Dialysis vintage, years 3.48 ±3.82 3.50 ±3.86 0.90 
Dialysis time per week, hours 12.1 ±1.6 11.8 ±1.8 <0.001 
Kt/V midweek session 1.20 ±0.33 1.20 ±0.29 0.68 
Phosphate, mmol/L 1.82 ±0.54 1.79 ±0.55 0.25 
Calcium, mmol/L  2.33 ±0.20 2.34 ±0.22 0.39 
Haemoglobin, g/dL 11.8 ±1.47 11.6 ±1.62 0.021 
Albumin, g/dL  39.2 ±3.2 39.8 ±3.5 <0.001 
High sensitive C-reactive protein, mg/L 1.15 ±1.18 0.97 ±1.15 0.001 
Sevelamer, n (%)   84 (16.6) 422 (18.7) 0.27 
Values are given as mean (standard deviation) or n (%) as appropriate. LDL: low densitiy lipoprotein. HDL: high density 
lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor blocker.  
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Table 3. Subgroups of atherosclerotic diseases; number of events, follow-up time and crude incidence rates. Some 
patients had several non-fatal events. First event within each diagnosis subgroup has been counted. 
    No. of events 
Follow-up time, 
months 
No. of events per 1000 
patient years (95% 
confidence interval) 
Combined atherosclerotic outcome 506 100 891 61.0 ( 55.7-66.3)  
Coronary heart disease      
 Non-fatal myocardial infarction 123 104 677 14.1 (11.6-16.6)  
 Fatal myocardial infarction 108 113 390 11.4 (9.3-13.6)  
 Coronary revascularisation 203 109 034 22.3 (19.3-25.4)  
Ischaemic stroke       
 Non-fatal ischaemic stroke 85 105 659 9.7 (7.6-11.7)  
 Fatal ischaemic stroke 33 113 390 3.5 (2.3-4.7)  
Death from peripheral atherosclerotic disease 50 113 390 5.3 (3.8-6.8)   
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Table 4. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for the combined, 
readjudicated atherosclerotic endpoint (506 events).  
  Univariate models Multivariable model 
    HR 95% CI P value HR 95% CI P value 
Sex, male  1.46 (1.21 - 1.77) <0.001 1.49 (1.21 - 1.83) <0.001 
Age, per 5 years  1.24 (1.18 - 1.31) <0.001 1.15 (1.09 - 1.22) <0.001 
Region    <0.001   0.023 
 Western Europe 1.30 (0.99 - 1.73) 0.064 1.27 (0.95 -1.71) 0.11 
 Eastern Europe 1.12 0.81 - 1.54) 0.50 1.23 (0.88 - 1.71) 0.23 
 Asia 0.65 (0.33 - 1.27) 0.21 0.98 (0.49 - 1.96) 0.96 
 South-America 0.46 (0.28 - 0.74) 0.001 0.63 (0.38 - 1.04) 0.072 
 Other Ref.   Ref.   
Allocation rosuvastatin vs. placebo, y/n 1.00 (0.84 - 1.19) 0.97    
Systolic blood pressure, per 10 mm Hg 0.99 (0.95 - 1.02) 0.53    
Diastolic blood pressure, per 5 mm Hg 0.94 (0.91 - 0.97) <0.001    
Pulse pressure, per 5 mm Hg 1.02 (0.99 - 1.04) 0.14    
Body weight, per 5 kg  1.03 (1.00 - 1.06) 0.056    
Body height, per 5 cm  1.05 (1.00 - 1.09) 0.062    
Body mass index, per kg/m2 1.01 (0.99 - 1.03) 0.29    
Current smoking, y/n  1.09 (0.86 - 1.38) 0.48    
Previous coronary heart disease, y/n 2.74 (2.26 - 3.32) <0.001    
Previous cardiovascular disease, y/n 2.63 (2.20 - 3.14) <0.001 1.93 (1.59 - 2.34) <0.001 
Diabetes, y/n  1.93 (1.61 - 2.32) <0.001 1.76 (1.45 - 2.14) <0.001 
Cholesterol, per mmol/L  1.01 (0.93 - 1.09) 0.82    
LDL cholesterol, per mmol/L 1.03 (0.93 - 1.13) 0.58    
HDL cholesterol, per mmol/L 0.76 (0.60 - 0.96) 0.023    
Triglycerides, per mmol/L  1.03 (0.95 - 1.11) 0.51    
Oxidised LDL cholesterol, per 10 U/L 1.07 (1.01 - 1.14) 0.017 1.09 (1.03 - 1.17) 0.006 
24 
 
Apolipoprotein B /Apolipoprotein A1 ratio, per unit 1.77 (1.28 - 2.45) 0.001    
Beta blocker, y/n  1.14 (0.95 - 1.36) 0.16    
ACEi or ARB, y/n  1.07 (0.90 - 1.28) 0.44    
Dialysis vintage, per year  1.00 (0.98 - 1.02) 0.96    
Dialysis time per week, per hour 1.05 (1.01 - 1.11) 0.031 1.07 (1.01 - 1.12) 0.018 
Kt/V midweek session, per unit 0.85 (0.62 - 1.16) 0.29    
Phosphate, per mmol/L  1.14 (0.97 - 1.34) 0.11    
Calcium, per mmol/L  0.80 (0.53 - 1.20) 0.27    
Haematocrit, per %  2.95 (0.46 - 18.8) 0.25    
Haemoglobin, per g/dL  1.03 (0.98 - 1.09) 0.26    
Albumin, per g/L  0.93 (0.91 - 0.95) <0.001 0.96 (0.94 - 0.99) 0.008 
High sensitive C-reactive protein, per mg/L 1.19 (1.11 - 1.27) <0.001 1.13 (1.04 - 1.22) 0.002 
Sevelamer, y/n   0.84 (0.67 - 1.07) 0.16       
LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor 
blocker.  The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables 
with P<0.1 in univariate analysis) are listed. 
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Table 5. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for coronary heart 
disease (fatal or non-fatal myocardial infarction or coronary revascularisation; 384 events).  
  Univariate models Multivariable model 
    HR 95% CI P value HR 95% CI P value 
Sex, male  1.79 (1.43 - 2.25) <0.001 1.80 (1.41 - 2.30) <0.001 
Age, per 5 years  1.22 (1.15 - 1.29) <0.001 1.13 (1.06 - 1.20) <0.001 
Region    <0.001   0.002 
 Western Europe 1.17 (0.86 - 1.59)  0.32 1.18 (0.86 - 1.62) 0.30 
 Eastern Europe 0.99 (0.70 - 1.42) 0.97 1.12 (0.78 - 1.62) 0.53 
 Asia 0.77 (0.39 - 1.52) 0.45 1.00 (0.49 - 2.03) 0.99 
 South-America 0.21 (0.10 - 0.43) <0.001 0.28 (0.14 - 0.59) 0.001 
 Other Ref.      
Allocation rosuvastatin vs. placebo, y/n 1.01 (0.82 - 1.23) 0.96    
Systolic blood pressure, per 10 mm Hg 0.97 (0.93 - 1.02) 0.24    
Diastolic blood pressure, per 5 mm Hg 0.92 (0.88 - 0.96) <0.001 0.96 (0.92 - 1.00) 0.042 
Pulse pressure, per 5 mm Hg 1.02 (0.99 - 1.05) 0.21    
Body weight, per 5 kg 1.04 (1.01 - 1.07) 0.028    
Body height, per 5 cm 1.06 (1.01 - 1.12) 0.029    
Body mass index, per kg/m2 1.01 (0.99 - 1.03) 0.25    
Current smoking, y/n 1.13 (0.87 - 1.48) 0.36    
Previous coronary heart disease, y/n 3.10 (2.47 - 3.88) <0.001 1.70 (1.10 - 2.64) 0.017 
Previous cardiovascular disease, y/n 2.83 (2.31 - 3.48) <0.001    
Diabetes, y/n  1.92 (1.56 - 2.36) <0.001 1.46 (1.11 - 1.91) 0.007 
Cholesterol, per mmol/L 1.01 (0.92 - 1.11) 0.83    
LDL cholesterol, per mmol/L 1.03 (0.92 - 1.15) 0.59    
HDL cholesterol, per mmol/L 0.69 (0.52 - 0.92) 0.010    
Triglycerides, per mmol/L 1.04 (0.95 - 1.13) 0.40    
Oxidised LDL cholesterol, per 10 U/L 1.06 (0.99 - 1.14) 0.085    
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Apolipoprotein B /Apolipoprotein A1 ratio, per unit 1.91 (1.32 - 2.76) 0.001 1.66 (1.11 - 2.49) 0.014 
Beta blocker, y/n  1.20 (0.98 - 1.47) 0.082    
ACEi or ARB, y/n  1.12 (0.91 - 1.37) 0.29    
Dialysis vintage, per year 0.98 (0.96 - 1.01) 0.27    
Dialysis time per week, per hour 1.06 (1.01 - 1.12) 0.033    
Kt/V midweek session, per unit 0.98 (0.69 - 1.39) 0.90    
Phosphate, per mmol/L 1.18 (0.98 - 1.41) 0.081 1.28 (1.06 - 1.55) 0.010 
Calcium, per mmol/L  0.69 (0.43 - 1.10) 0.11    
Haematocrit, per %  4.07 (0.48 - 34.5) 0.20    
Haemoglobin, per g/dL 1.04 (0.97 - 1.12) 0.23    
Albumin, per g/L  0.95 (0.92 - 0.98) <0.001    
High sensitive C-reactive protein, per mg/L 1.17 (1.08 - 1.27) <0.001 1.12 (1.03 - 1.22) 0.009 
Sevelamer, y/n   0.86 (0.66 - 1.21) 0.26       
LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor 
blocker.  The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with 
P<0.1 in univariate analysis) are listed. 
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Table 6. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for ischaemic stroke 
(116 events).  
  Univariate models Multivariable model 
    HR 95% CI P value HR 95% CI P value 
Sex, male  0.97 (0.67 - 1.40) 0.86    
Age, per 5 years  1.21 (1.08 - 1.34) 0.001 1.15 (1.03 - 1.29) 0.013 
Region    0.55    
 Western Europe 1.47 (0.80 - 2.71) 0.22    
 Eastern Europe 1.24 (0.62 - 2.48) 0.55    
 Asia NA      
 South-America 0.92 (0.38 - 2.18) 0.84    
 Other Ref.      
Allocation rosuvastatin vs. placebo, y/n 1.07 (0.75 - 1.54) 0.71    
Systolic blood pressure, per 10 mm Hg 1.04 (0.96 - 1.12) 0.31    
Diastolic blood pressure, per 5 mm Hg 1.02 (0.95 - 1.09) 0.64    
Pulse pressure, per 5 mm Hg 1.03 (0.98 - 1.07) 0.33    
Body weight, per 5 kg 1.02 (0.96 - 1.08) 0.54    
Body height, per 5 cm 1.02 (0.93 - 1.13) 0.65    
Body mass index, per kg/m2 1.01 (0.97 - 1.05) 0.66    
Current smoking, y/n 1.44 (0.92 - 2.26) 0.11    
Previous coronary heart disease, y/n 1.62 (1.12 - 2.35) 0.011    
Previous cardiovascular disease, y/n 1.73 (1.20 - 2.49) 0.003    
Diabetes, y/n  1.68 (1.14 - 2.47) 0.009    
Cholesterol, per mmol/L 1.00 (0.85 - 1.19) 0.97    
LDL cholesterol, per mmol/L 1.01 (0.83 - 1.24) 0.92    
HDL cholesterol, per mmol/L 1.18 (0.76 - 1.82) 0.46    
Triglycerides, per mmol/L 0.94 (0.79 - 1.13) 0.52    
Oxidised LDL cholesterol, per 10 U/L 1.10 (0.98 - 1.24) 0.11    
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Apolipoprotein B /Apolipoprotein A1 ratio, per unit 1.09 (0.52 - 2.26) 0.83    
Beta blocker, y/n  1.07 (0.74 - 1.56) 0.71    
ACEi or ARB, y/n  1.09 (0.75 - 1.58) 0.66    
Dialysis vintage, per year 1.03 (0.99 - 1.07) 0.22    
Dialysis time per week, per hour 1.07 (0.97 - 1.18) 0.18    
Kt/V midweek session, per unit 0.70 (0.36 - 1.37) 0.30    
Phosphate, per mmol/L 0.94 (0.66 - 1.33) 0.73    
Calcium, per mmol/L  0.82 (0.35 - 1.90) 0.64    
Haematocrit, per %  1.66 (0.03 - 80.3) 0.80    
Haemoglobin, per g/dL 1.03 (0.91 - 1.16) 0.65    
Albumin, per g/L  0.89 (0.85 - 0.94) <0.001 0.91 (0.86 - 0.96) <0.001 
High sensitive C-reactive protein, per mg/L 1.11 (0.95 - 1.29) 0.20    
Sevelamer, y/n   0.94 (0.59 - 1.52) 0.81       
LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor 
blocker.  The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with 
P<0.1 in univariate analysis) are listed. NA: Not applicable due to low number of events. 
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Table 7. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for death from 
peripheral atherosclerotic disease (50 events).  
  Univariate models Multivariable model 
    HR 95% CI P value HR 95% CI P value 
Sex, male  1.00 (0.56 - 1.77) 1.00    
Age, per 5 years  1.52 (1.27 - 1.82) <0.001 1.38 (1.14 - 1.68) 0.001 
Region    0.64    
 Western Europe 2.54 (0.77 - 8.31) 0.13    
 Eastern Europe 2.51 (0.71 - 8.89) 0.15    
 Asia NA      
 South-America 2.02 (0.48 - 8.50) 0.34    
 Other Ref.      
Allocation rosuvastatin vs. placebo, y/n 1.27 (0.73 - 2.23) 0.40    
Systolic blood pressure, per 10 mm Hg 1.01 (0.90 - 1.14) 0.84    
Diastolic blood pressure, per 5 mm Hg 0.90 (0.80 - 1.01) 0.056    
Pulse pressure, per 5 mm Hg 1.05 (0.99 - 1.13) 0.14    
Body weight, per 5 kg 1.03 (0.95 - 1.13) 0.50    
Body height, per 5 cm 0.99 (0.85 - 1.14) 0.84    
Body mass index, per kg/m2 1.03 (0.97 - 1.08) 0.37    
Current smoking, y/n 1.04 (0.50 - 2.22) 0.92    
Previous coronary heart disease, y/n 13.04 (4.69 - 36.25) <0.001    
Previous cardiovascular disease, y/n 7.18 (3.59 - 14.36) <0.001 4.34 (2.11 - 8.89) <0.001 
Diabetes, y/n  3.55 (2.03 - 6.18) <0.001 3.16 (1.77 - 5.65) <0.001 
Cholesterol, per mmol/L 1.26 (1.00 - 1.59) 0.054    
LDL cholesterol, per mmol/L 1.39 (1.05 - 1.83) 0.020 1.33 (1.03 - 1.72) 0.029 
HDL cholesterol, per mmol/L 0.58 (0.26 - 1.30) 0.19    
Triglycerides, per mmol/L 1.10 (0.91 - 1.34) 0.34    
Oxidised LDL cholesterol, per 10 U/L 1.18 (1.00 - 1.40) 0.052    
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Apolipoprotein B /Apolipoprotein A1 ratio, per unit 2.97 (1.23 - 7.18) 0.016    
Beta blocker, y/n  0.77 (0.42 - 1.39) 0.38    
ACEi or ARB, y/n  0.61 (0.32 - 1.15) 0.12    
Dialysis vintage, per year 0.98 (0.90 - 1.06) 0.56    
Dialysis time per week, per hour 0.97 (0.83 - 1.14) 0.75    
Kt/V midweek session, per unit 0.41 (0.14 - 1.18) 0.096    
Phosphate, per mmol/L 1.92 (1.23 - 3.02) 0.004 2.37 (1.50 - 3.75) <0.001 
Calcium, per mmol/L  1.29 (0.37 - 4.57) 0.69    
Haematocrit, per %  0.44 (0.00 - 168.1) 0.79    
Haemoglobin, per g/dL 0.97 (0.81 - 1.16) 0.76    
Albumin, per g/L  0.87 (0.81 - 0.94) 0.001 0.92 (0.84 - 1.00) 0.048 
High sensitive C-reactive protein, per mg/L 1.50 (1.24 - 1.81) <0.001 1.39 (1.12 - 1.72) 0.003 
Sevelamer, y/n   0.47 (0.19 - 1.19) 0.11       
LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor 
blocker.  The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with 
P<0.1 in univariate analysis) are listed. NA: Not applicable due to low number of events. 
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Figure 1. Kaplan-Meier survival curves for the new atherosclerotic endpoint in the two treatment allocation groups (rosuvastatin vs. 
placebo). 
